Recombinant Antibodies

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement

Efalizumab (anti-ITGAL) is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab (anti-ITGAL) inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes,

Efalizumab (anti-ITGAL) is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab (anti-ITGAL) inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes,

Efalizumab (anti-ITGAL) is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab (anti-ITGAL) inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes,

Efalizumab (anti-ITGAL) is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab (anti-ITGAL) inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes,

Eldelumab (anti-CXCL10) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab (anti-CXCL10) selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab (anti-CXCL10) can be used in studies

Eldelumab (anti-CXCL10) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab (anti-CXCL10) selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab (anti-CXCL10) can be used in studies

Eldelumab (anti-CXCL10) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab (anti-CXCL10) selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab (anti-CXCL10) can be used in studies

Eldelumab (anti-CXCL10) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab (anti-CXCL10) selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab (anti-CXCL10) can be used in studies

Elezanumab (anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab (anti-RGMA) potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM.